Nan Fung
Life Sciences

Focused on innovation and growth in Life Sciences


A global Investor in Life Sciences

Our deep resources, commitment, and knowledge within the Nan Fung Life Sciences family of investment companies make us the ideal partners to scientists, entrepreneurs, and corporations around the world. With a diverse set of experiences, skills, and a track record in company formation, venture capital, and scientific innovation, we focus on delivering opportunities to investors who seek to benefit from long-term value.

Nan Fung Life Sciences

Global Life Sciences Investment Platform

Pivotal Life Sciences >

Global Life Sciences Asset Management Platform

Pivotal bioVenture Partners (US)

Global Life Sciences VC Investor
(excluding Asia)

Pivotal bioVenture Partners (China)

Life Sciences VC Investor
Based in China

Public Investment >

Life Sciences Public

NFLS Platform
Companies >

Building Life Sciences Companies

Fund & Co
Investments >

Investing in Life Sciences Funds


We have an important job to do. Find your role.


Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

INDIANAPOLIS and BOSTON, Oct. 18, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. “We are honored to work with the talented team at Akouos who are breaking new ground in the science of treating hearing loss,” said Andrew C. Adams, Ph.D., senior vice president of genetic medicine and co-director of the Institute for Genetic Medicine, Lilly.

Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology

Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populations

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

Study met both co-primary endpoints and all secondary endpoints. At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicle
At week eight, 46.5% of individuals treated with roflumilast foam achieved Body-Investigator Global Assessment (B-IGA) Success compared to 20.8% of individuals treated with vehicle
Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). These data demonstrate that one week after a single subcutaneous dose, RLYB212 was able to eliminate transfused HPA-1a positive platelets rapidly compared to placebo in a challenge model of a catastrophic fetal maternal hemorrhage. Additional pharmacokinetic data suggests the opportunity for less frequent dosing.